<DOC>
	<DOCNO>NCT02822950</DOCNO>
	<brief_summary>The purpose study analyze PK/PD AvyCaz critically ill patient Intensive Care Unit ( 12 ) . This study include medical post-surgical patient develop infection Avycaz utilize . Since patient variable PK parameter , investigator also analyze ( time-kill ) serum concentration ( ex vivo ) relevant clinical isolates ( e.g . GNR ESBL KPC ) ICU determine microbiologic activity Avycaz critically ill patient variable characteristic . Monte-Carlo simulation also conduct clinical ICU isolates ( JMI lab ) help determine appropriate dose schedule base upon PK parameter .</brief_summary>
	<brief_title>A Study Avycaz ( Ceftazidime/Avibactam ) Pharmacokinetics/Pharmacodynamics ( PK/PD ) Critically Ill Patients</brief_title>
	<detailed_description />
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Avibactam , ceftazidime drug combination</mesh_term>
	<criteria>Adult ( ≥18y/o ) patient medical postsurgical infection skin/soft tissue infection , urinary infection , IA infection pneumonia ( include VAP ) Patients require intensive care ( critically ill patient ) med/surg ICU ( APACHE II score ≥ 15 ) Patients prescribed Avycaz infection receive FDA recommend dosage time administration Written inform consent Pregnant Patients , patient older 90 y/o , CrCl &lt; 30 mL/min , patient BMI &gt; 45 Kg/m2 , patient unable provide serum sample , risk imminent death study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>